Early Antiretroviral Therapy Prevents Both Serious AIDS and Serious Non-AIDS Outcomes in people living with HIV New Findings Illustrate Manifold Benefit to Therapy

The full and groundbreaking results of the START (The strategic Timing of AntiRetrovital Treatment) study, will be presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada, Monday 20 July by Professor Jens Lundgren, Rigshospitalet, University of Copenhagen, followed by a panel discussion with participation of key stakeholders from PEPFAR, WHO and The Global Fund to discuss the wider implications of the results. The results will be published in the New England Journal of Medicine today.

The results of the study show, as the first study in history, that starting antiretroviral treatment early improves outcomes for people living with HIV.

For more information about the START trial, see the Questions and Answers at the National Institutes of Health (NIH) and at CHIP, Rigshospitalet, University of Copenhagen http://www.cphiv.dk/Ongoing-Studies/START/NEWS

Please contact Dorthe Raben with any questions: dorthe.raben@regionh.dk , +45 61708260